Polymersome Nanoparticle Co-Delivery for Balanced Th1/Th2 Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for eliciting an immune response, particularly for membrane proteins and vaccines, face challenges such as low response levels, instability, high costs, and inefficiencies in antigen delivery and adjuvant uptake, leading to suboptimal immune responses and safety concerns.
Innovation Solution
The method involves co-administering two populations of polymersomes, one associated with an antigen and the other with an adjuvant, to modulate the immune response by increasing CD4+ T cells expressing Th1 cytokines, thereby enhancing the immune response and achieving a balanced Th1/Th2 immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If membrane proteins are used as antigens, then the immune response level is low, but using large amounts of membrane proteins is required which increases cost and difficulty of production
Solution Approach 1:
The patent uses polymersome nanoparticles as a composite delivery system that combines antigens with adjuvants in a controlled formulation. This composite structure enhances the immunogenicity of membrane protein antigens, allowing effective immune responses at lower antigen doses while maintaining production feasibility
Solution Approach 2:
Polymersomes act as intermediary carriers that facilitate the delivery of membrane protein antigens to the immune system. The nanoparticle formulation serves as a mediator between the antigen and immune cells, improving uptake and presentation efficiency, thereby reducing the amount of antigen needed to achieve desired immune response levels
2Reliability
If adjuvants are used to boost immunogenicity of solubilized antigens, then immune response is enhanced, but the method is inefficient and provides little advantage
Solution Approach 1:
The patent merges antigens and adjuvants into a single polymersome nanoparticle formulation. This combination ensures co-delivery to the same immune cells, synchronizing antigen presentation with adjuvant activation. The merged formulation achieves superior immunogenicity with improved efficiency compared to separate administration, as the adjuvant and antigen work together at the cellular level
3Ease of operation
If liposomes are used as delivery vehicles, then uptake by APCs is efficient, but stability in the presence of serum components is poor
Solution Approach 1:
The patent changes the material parameters by replacing lipid-based liposomes with polymer-based polymersomes. This parameter change in the delivery vehicle composition provides enhanced stability in serum environments while maintaining efficient uptake by antigen-presenting cells. The polymeric structure resists degradation and aggregation in biological fluids better than lipid structures
4Reliability
If microencapsulation of antigens into polymers is used, then immunogenicity is enhanced, but aggregation and denaturing of antigens remain unsolved
Solution Approach 1:
The patent uses polymersome nanoparticle shells that provide a protective flexible membrane around the encapsulated antigens. This thin film structure protects antigens from aggregation and denaturing while allowing proper folding and maintaining immunogenicity. The polymersome membrane creates a controlled microenvironment that preserves antigen structure during delivery
Data Source
AI summary
The present invention relates to a method of modulating Th1/Th2 immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersomes.